Format

Send to

Choose Destination
Drug Discov Today. 2014 Feb;19(2):126-32. doi: 10.1016/j.drudis.2013.06.003. Epub 2013 Jun 15.

Genomics and transcriptomics in drug discovery.

Author information

1
Computational Genomics Department, Centro de Investigación Príncipe Felipe (CIPF), Valencia 46012, Spain; Functional Genomics Node, (INB) at CIPF, Valencia 46012, Spain; CIBER de Enfermedades Raras (CIBERER), Valencia 46012, Spain. Electronic address: jdopazo@cipf.es.

Abstract

The popularization of genomic high-throughput technologies is causing a revolution in biomedical research and, particularly, is transforming the field of drug discovery. Systems biology offers a framework to understand the extensive human genetic heterogeneity revealed by genomic sequencing in the context of the network of functional, regulatory and physical protein-drug interactions. Thus, approaches to find biomarkers and therapeutic targets will have to take into account the complex system nature of the relationships of the proteins with the disease. Pharmaceutical companies will have to reorient their drug discovery strategies considering the human genetic heterogeneity. Consequently, modeling and computational data analysis will have an increasingly important role in drug discovery.

PMID:
23773860
DOI:
10.1016/j.drudis.2013.06.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center